Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol TACSTD2 contributors: mct/shn - updated : 21-06-2023
HGNC name tumor-associated calcium signal transducer 2
HGNC id 11530
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • a single transmembrane domain
  • EGF-like and thyroglobulin repeats
  • four potential N-linked glycosylation sites
  • a phosphatidylinositol binding site
  • conjugated GlycoP
    HOMOLOGY
    interspecies ortholog to Tacstd2, Mus musculus
    ortholog to Tacstd2, Rattus norvegicus
    ortholog to TACSTD2, Pan troglodytes
    intraspecies homolog to GA733.2
    Homologene
    FAMILY thyroglobulin type-1 family
    CATEGORY adhesion , tumor suppressor , signaling
    SUBCELLULAR LOCALIZATION extracellular
        plasma membrane
        intracellular
    intracellular,cytoplasm,organelle,membrane
    intracellular,cytoplasm,cytosolic
    intracellular,nucleus
    basic FUNCTION
  • may play a role in regulating the growth of carcinoma cells (
  • carcinoma associated antigen
  • transducing an intracellular calcium signal and acting as a cell surface receptor
  • functioning as a cell/cell adhesion receptor in cancer cells and as a calcium signal transducer
  • its expression is necessary for tumorigenesis and invasiveness of colon cancer cells
  • activating a molecular signaling pathway which has important implications for cancer cell growth and survival
  • its upregulation quantitatively stimulates human cancer growth
  • is a transmembrane signal transducer that can induce cancer growth
  • TACSTD2 was able to compensate for the loss of EPCAM in stabilizing CLDN7 expression and cell membrane localization in tissues that co-express both proteins
  • CELLULAR PROCESS cell organization/biogenesis
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling signal transduction , sensory transduction/vision
    calcium signal tranducer
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • non-structural 5A, NS5A
  • binding of LGALS3 to MUC1 enhances likely the recruitment of SP1, leading to promotion of the transcription of TACSTD2
  • TACSTD2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis
  • can tightly interact with ADAM10
  • TACSTD2 was able to compensate for the loss of EPCAM in stabilizing CLDN7 expression and cell membrane localization in tissues that co-express both proteins
  • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s) GDLD
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral fusion      
    with CCND1 and overexpressed in cancer cells
    tumoral     --over  
    in epithelial ovarian cancer
    tumoral     --over  
    correlates with poor prognosis in pancreatic cancer (
    constitutional     --over  
    may represent a mechanism to maintain/restore epithelial barrier function and contribute to regeneration process in infected/damaged lungs
    tumoral     --over  
    are predictive of recurrence of localized prostate cancer, castration-resistant prostate cancer (CRPC), or neuroendocrine prostate cancer (NEPC)
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
  • could be a novel prognostic biomarker for pancreatic cancer (
  • could be used as a marker for pathological grading of squamous cell carcinoma (SCC)
  • TACSTD2 may be a valuable prognosis predictive biomarker in human solid tumors
  • Therapy target
    SystemTypeDisorderPubmed
    cancerreproductiveovary
    targeting of its overexpression by immunotherapeutic strategies may represent an attractive and potentially effective approach in patients harbouring epithelial ovarian cancer
    cancerendocrinepancreas
    might be a useful treatment approach for patients with pancreatic cancer overexpressing this cell-surface marker
    cancer  
    oncogene that has potential as a therapeutic target, and having a restricted expression in normal tissue, anti-Trop-2 therapeutics would be predicted to have limited toxicity
    cancerreproductiveprostate
    is a driver and therapeutic target for metastatic prostate cancer with neuroendocrine phenotype
    cancerdigestivecolon
    is a target in metastatic colon cancer
    cancer  
    potential therapeutic target in human solid tumors
    ANIMAL & CELL MODELS